
Kiora Pharmaceuticals fell 60.2% from $1.81 to $0.72, behind the S&P 500's +3.2%. Its worst day was Oct 29 (−27.0%), and its low came Nov 20 at $0.72.
Nov 24, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.60 missed the $-0.54 estimate on $0.00 revenue (est. $1.5M).
−3.4% · S&P 500 −1.8%
Kiora Pharmaceuticals closed at its highest level of the year, 58.0% above where the year started.
Story events cover the past 12 months · Times ET
+32.4%, the year's best day · S&P 500 +2.5%
EPS of $-0.58 beat the $-0.70 estimate on $0.00 revenue (est. $1.5M).
0.0% · S&P 500 +0.8%
EPS of $-0.34 beat the $-0.62 estimate on $0.00 revenue.
+3.1% · S&P 500 +0.6%
Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in
−27.0%, the year's worst day · S&P 500 −0.4%
EPS of $-0.28 beat the $-0.41 estimate on $1.0M revenue.
−1.5% · S&P 500 −0.4%
Where it ended: a close of $0.72 on Nov 20, 2026.
Nothing in the past 12 months.
All KPRX analyst actionsNothing in the past 12 months.
All KPRX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KPRX and SPY from Benzinga historical bars. Not investment advice.